Journal
VACCINES
Volume 10, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10101628
Keywords
subunit vaccine; integrity; potency; assay qualification; malaria; transmission-blocking vaccine; Pfs230
Categories
Funding
- PATH
- Global Health Innovative Technology (GHIT) Fund [G2019-205]
- National Institute of Allergy and Infectious Disease (NIAID)/NIH
Ask authors/readers for more resources
Monitoring the integrity of recombinant proteins is critical during the development of subunit vaccines. This study developed a sandwich ELISA-based in vitro potency assay, called the Antigen Integrity Assay (AIA), to monitor the potency of Pfs230 protein. The AIA demonstrated excellent precision, sensitivity, and high throughput, making it a useful tool for future subunit vaccine development.
During development of a subunit vaccine, monitoring integrity of the recombinant protein for process development and quality control is critical. Pfs230 is a leading malaria transmission blocking vaccine candidate and the first to reach a Phase 2 clinical trial. The Pfs230 protein is expressed on the surface of gametes, and plays an important role in male fertility. While the potency of Pfs230 protein can be determined by a standard membrane-feeding assay (SMFA) using antibodies from immunized subjects, the precision of a general in vivo potency study is known to be poor and is also time-consuming. Therefore, using a well-characterized Pfs230 recombinant protein and two human anti-Pfs230 monoclonal antibodies (mAbs), which have functional activity judged by SMFA, a sandwich ELISA-based in vitro potency assay, called the Antigen Integrity Assay (AIA), was developed. Multiple validation parameters of AIA were evaluated to qualify the assay following International Conference on Harmonization (ICH) Q2(R1) guidelines. The AIA is a high throughput assay and demonstrated excellent precision (3.2 and 5.4% coefficients of variance for intra- and inter-assay variability, respectively) and high sensitivity (>12% impurity in a sample can be detected). General methodologies and the approach to assay validation described herein are amenable to any subunit vaccine as long as more than two functional, non-competing mAbs are available. Thus, this study supports future subunit vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available